NBRV News and Press, Nabriva Therapeutics plc From 01/05/21

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that management ...

Gainers: Sonoma Pharmaceuticals (SNOA) +87%.aTyr Pharma (LIFE) +65%.NantHealth (NH) +63%.vTv Therapeutics (VTVT) +55%.Equus Total Return (EQS) +45%Hancock Jaffe Laboratories (HJLI) +34%.MDJM (MDJH) +25%.Foresight Autonomous (FRSX) +23%.Solid Biosciences (SLDB) +22%.22...

Gainers: Sonoma Pharmaceuticals (SNOA) +114%. NantHealth (NH) +110%. vTv Therapeutics (VTVT) +59%. aTyr Pharma (LIFE) +33%. NantKwest (NK) +22%.Losers: SELLAS Life Sciences (SLS) -33%. Immutep (IMMP) -29%. Salarius Pharmaceuticals (SLRX) -29%. Nabriva Therapeutics (NBRV) -29%. ALX O...

Nabriva Therapeutics (NBRV) has priced its public offering of 6M ordinary shares (or pre-funded warrants in lieu thereof) at $2.50/share, for gross proceeds of $15M. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. Closing date is December 15.Shares ...

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the pricing of i...

Gainers: [[TPGY]] +99%. [[GIK]] +17.4%. [[AHT]] +15.8%. [[FEIM]] +13.9%. [[RMG]] +9.5%.Losers: [[NBRV]] -14.7%. [[OPCH]] -10.1%. [[PHX]] -8.9%. [[CASA]] -6.3%. [[ARCT]] -5.2%. For further details see: AHT, ARCT, NBRV and RMG among after-hours movers

Nabriva Therapeutics (NBRV) announces that it has commenced a public offering of its ordinary shares.There can be no assurance as to whether or when the offering may be completed.Press Release For further details see: Nabriva Therapeutics announces proposed public offering

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has comm...

Nabriva Therapeutics (NBRV) announces restructuring its license agreement for community acquired bacterial pneumonia treatment Xenleta in the greater China region. Sinovant Sciences will now provide additional manufacturing and regulatory support.The amendment accelerates components of a $5M&...

- Amen ded agreement encompasses enhanced manufacturing collaboration and regulatory support -A ccelerates milestone payments to Nabriva , including fourth quarter 2020 payment of $1 million DUBLIN, Ireland, Dec. 07, 2020...